Acetylcysteine/bethanechol chloride

Drug Profile

Acetylcysteine/bethanechol chloride

Alternative Names: Bethanechol chloride/acetylcysteine; DM-71

Latest Information Update: 05 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiaMedica
  • Developer Unknown
  • Class Antihyperglycaemics; Reducing agents; Small molecules; Sulfur amino acids; Trimethyl ammonium compounds
  • Mechanism of Action Adrenergic receptor agonists; Antioxidants; Cholinergic receptor agonists; Free radical inhibitors; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Oct 2017 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus in Canada (PO)
  • 29 Dec 2016 DiaMedica is now called DiaMedica Therapeutics
  • 01 Dec 2016 Unknown biopharmaceutical company acquires Acetylcysteine/bethanechol-chloride from DiaMedica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top